Abstract
The meeting covered traditional topics such as high-content screening and assay development, as well as more contemporary, emergent areas involving novel screening platforms and technologies, strategies to deal with biosimilars and biologics, and natural product diversity. Notably, many talks challenged established screening practices and the use of ‘combichem’ small-molecule libraries. Instead, speakers offered an alternate view of compound library design and screening strategies that could better mimic the target and cell status found in the relevant disease state.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
